Verge Genomics is conducting a Phase 1b study to assess the safety, tolerability and potential efficacy of VRG50635 in people with Amyotrophic lateral sclerosis (ALS).

The main purpose of a Phase 1 study is to test whether a new drug is safe. The b refers to administration in patients.
There is no placebo group; all patients receive VRG50635 in the study.

In total, the study will last about 1.5 years. The study will be divided into different periods: screening, run-in period (8wk), dose increase (32wk) and long-term treatment (36wk).

During the study, you will visit the study centre every 8 to 12 weeks and a study nurse will visit you at home every 2 weeks during the walk-in and dose increase period.